Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

19 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Varicella Virus Vaccine Live Articles

2007 Vioxx settlement sees Merck & Co 2008 profit up, despite lower sales

9 February 2009

...CDC also advises use of two-doses of chickenpox vaccine to boost protection

10 July 2006

US FDA approves Merck & Co's Proquad

12 September 2005

Merck & Co returns to India

1 August 2005

GSK launches chickenpox vaccine Varilrix in UK

12 August 2002

SB's three-year ban from selling Varilrix

17 August 1999

Merck Sues SB To Protect VZV Vaccine

6 January 1997

US Drug Majors See 2nd-Half Double-Digit Growth

29 July 1996

NCEs In 1995: A Good Range Of Novel Drugs

29 January 1996

New York stock Comment

31 July 1995

Merck pipline report

3 July 1995

Merck's Varivax Finally Approved In USA

27 March 1995

Merck's Varivax Approval Delayed

6 February 1995

PH II RESULTS OF PROSCAR BALDNESS TRIALS

25 April 1994

FDA PANEL BACKS MERCK CHICKENPOX VACCINE

7 February 1994

CHICKENPOX VACCINE NEARS APPROVAL IN USA

6 December 1993

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
  • Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
  • Additional indications in Japan for Roche's Avastin and Astellas' Prograf
  • Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS